Authors
Latest:
Key Takeaways on Recent Data from PERSEUSFrits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.
Latest:
Exploring Next-Line Options in HER2- MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future OutlookUntil 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.
Latest:
Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community CenterPanelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
Latest:
KIM-1 May Predict Higher-Risk Disease in Kidney CancerKIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
Latest:
CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple MyelomaPanelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
Latest:
Face-Off: Award CeremonyFollowing a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Latest:
Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBCNew findings reveal that adding durvalumab to neoadjuvant chemotherapy does not enhance HRQOL in muscle-invasive bladder cancer patients.
Latest:
Empowering Awareness to Address Rising Gynecological Cancer IncidenceGinger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Latest:
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and NeckThis study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.
Latest:
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell TumorIn this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
Latest:
Elevating the Quality of Cancer Care via Cross-Department CollaborationExperts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
Latest:
Addressing Common Talquetamab MisunderstandingsPanelists discuss how health care providers and patients should understand that talquetamab's unique adverse effects are temporary and resolve over time, even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.
Latest:
Highlighting Ongoing Clinical Trials in CML From ASHKendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Latest:
Improving the Management of HNSCC: Next StepsDr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.
